COMMUNIQUÉS West-GlobeNewswire

Sharps Technology’s SC Asset Purchase and $200 Million Syringe Sales Agreement Paves the Way to Begin Producing Prefillable Specialty Copolymer Syringes in the U.S.
31/05/2024
Sharps CEO issues letter to shareholders with details about the InjectEZ acquisition, establishing Sharps position in the prefillable syringe (PFS) industry in the U.S. Signed Syringe Sales Agreement will secure product [...]
Autonomix Medical, Inc. Reports Full Year 2024 Financial Results and Provides Corporate Update
31/05/2024
Year marked by operational and clinical execution advancing the development of a potential breakthrough technology for the nervous system Continued progress in first study ever to evaluate radiofrequency (RF) ablation [...]
Generation Lab Introduces First Platform that Measures Aging & Treatment Efficacy to Help Extend the Human Healthspan
31/05/2024
Backed by decades of longevity science, platform measures “biological noise” to determine age and fitness of key body systems aimed at cell regeneration and age reversal SAN FRANCISCO, May 31, 2024 (GLOBE NEWSWIRE) -- [...]
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
31/05/2024
Clinical testing of LP-310 expected to commence in mid-2024 Patient recruitment is underway for Phase 2a multicenter, dose-ranging study PITTSBURGH, May 31, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq [...]
Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference
31/05/2024
MONTREAL and CHARLOTTE, N.C., May 31, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in the Jefferies Global Healthcare [...]
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
31/05/2024
Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix ® (asciminib) demonstrated superior MMR rates at week 48 vs. investigator-selected SoC TKIs [...]
SS Innovations Engages BDO as its new Auditor
31/05/2024
SS Innovations believes that the selection of BDO will facilitate uplisting of its common stock to a National Securities Exchange and reflects the Company’s commitment to transparent financial and accounting practices [...]
Morphic to Participate in Jefferies Global Healthcare Conference
31/05/2024
WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today [...]
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
31/05/2024
SAN DIEGO and TORONTO, May 31, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral [...]
Bionomics Limited Announces Private Placement of up to $70.0 Million
31/05/2024
ADELAIDE, Australia and CAMBRIDGE, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”), a clinical-stage biotechnology company developing novel, potential first-in- [...]
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
31/05/2024
More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancers SEATTLE, May 31, 2024 (GLOBE NEWSWIRE) -- Adaptive [...]
TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
31/05/2024
NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI ® (ublituximab-xiiy) in [...]
SciSparc Secures Strategic Advantage with Grant of European Patent
31/05/2024
TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders [...]
Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer
31/05/2024
Mr. Lee joins Invivyd with a history of high-quality commercial execution at Alexion, Biohaven and Amylyx Appointment intended to accelerate the addition of commercial capabilities associated with orphan medicines to [...]
atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
31/05/2024
NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, [...]
Immuron Board Changes
31/05/2024
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston has resigned from his [...]
Mesa Laboratories, Inc. Revises Earnings Announcement date for Unaudited Fourth Quarter and Full Fiscal Year 2024 Results
31/05/2024
LAKEWOOD, Colo., May 31, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (“Mesa”) (NASDAQ:MLAB) will not issue its 2024 financial results for the fourth quarter and the fiscal year ending March 31, 2024 today as [...]
Immuron CEO Steven Lydeamore to present at Peak Sky High
31/05/2024
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief Executive Officer [...]
Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
31/05/2024
Sanofi launches 2024 global Employee Stock Purchase Plan Paris, May 31, 2024. Sanofi’s global employee shareholder plan, Action 2024, opens on June 4, 2024, to around 80,000 employees in 56 countries. Now in its 10 th [...]

Pages